Mackintosh, J.A.Keir, G.Troy, L.K.Holland, A.E.Grainge, C.Chambers, D.C.Sandford, D.Jo, H.E.Glaspole, I.Wilsher, M.Goh, N.S.L.Reynolds, P.N.Chapman, S.Mutsaers, S.E.de Boer, S.Webster, S.Moodley, Y.Corte, T.J.2024-08-192024-08-192024Respirology, 2024; 29(2):105-1351323-77991323-7799https://hdl.handle.net/2440/141928Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti-fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non-IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non-pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi-faceted approach to the management of IPF and progressive pulmonary fibrosis.en© 2024 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.idiopathic pulmonary fibrosisinterstitial lung diseaseprogressive pulmonary fibrosispulmonary fibrosistreatmentHumansFibrosisPyridonesAustraliaNew ZealandIdiopathic Pulmonary FibrosisJournal article10.1111/resp.146562024-08-16681545Reynolds, P.N. [0000-0002-2273-1774]